1XT Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)1.67K
Market Cap
€14.09M
Enterprise Value€208.12
Total Cash (Recent Filing)€23.21M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 28, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding861,266,850
10 Day Avg. Volume5,000
30 Day Avg. Volume1,666
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€1.01M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt reduces refinancing and interest-burden risk, giving Xintela more flexibility to fund development through equity, partnerships or future licensing proceeds despite its weak equity position.
Differentiated ITGA10 PlatformA focused platform around ITGA10 provides a coherent scientific basis across cell therapies and antibodies. If validation succeeds, the shared target could support multiple programs and improve partnering potential.
Partnering And Licensing OptionalityThe model can monetize development assets through partnerships before full commercialization, potentially reducing the need to build a large sales infrastructure. However, the pack does not confirm material signed commercial contracts.
Bears Say
Persistent Operating LossesSustained losses show that current activities do not cover the cost base. Without meaningful commercialization or partnering income, profitability remains dependent on successful pipeline advancement and eventual product approval.
Heavy, Unresolved Cash BurnContinued negative operating and free cash flow increases reliance on external financing over the next several quarters. Funding needs could dilute shareholders or constrain development if capital becomes difficult to secure.
Negative Equity And Weak Financial ResilienceNegative equity materially limits balance-sheet flexibility even without debt. It signals that accumulated losses have eroded the capital base, increasing vulnerability to funding delays, restructuring pressure or unfavorable financing terms.
Xintela AB News
1XT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is €14.09M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Aug 28, 2026 which is today.
How were Xintela AB’s earnings last quarter?
Currently, no data Available
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is >-0.01.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in DE:1XT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
NextCell Pharma AB
―